Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study

BACKGROUND: In Canada, interferon-free, direct-acting antiviral hepatitis C virus (HCV) regimens are costly. This presents challenges for universal drug coverage of the estimated 220 000 people with chronic HCV infection nationwide. The study objective was to appraise criteria for reimbursement of 4...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:CMAJ Open
Prif Awduron: Marshall, Alison D., Saeed, Sahar, Barrett, Lisa, Cooper, Curtis L., Treloar, Carla, Bruneau, Julie, Feld, Jordan J., Gallagher, Lesley, Klein, Marina B., Krajden, Mel, Shoukry, Naglaa H., Taylor, Lynn E., Grebely, Jason
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Joule Inc. or its licensors 2016
Pynciau:
Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5173474/
https://ncbi.nlm.nih.gov/pubmed/28018873
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.9778/cmajo.20160008
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg